Podcasts about life sciences

There is a palpable mix of excitement and anxiety about the latest impending wave of Artificial Intelligence. AI tools are being developed that will fundamentally impact our jobs, our relationships, our access to knowledge and creativity, our children's lives, and our planet. But for an industry like healthcare — where fax machines and pagers are common, where people struggle to find affordable care or adequate resources, and nurses are leaving the profession due to administrative burdens and moral distress — can AI be an answer?  In this two-part feature of our AI in Play series, where we explore AI's role in transforming healthcare, host Oriana Beaudet, Vice President of Innovation at the American Nurses Association, Credentialing Center, and Foundation, talks with a nurse and a clinician helping to shape the future of AI in healthcare for one of the largest technology companies in the world.   Episode 130 features nurse Mary Varghese-Presti, Corporate VP and COO of Microsoft Health and Life Sciences, whose team built Dragon Copilot, the first commercially available ambient AI solution purpose-built for nursing workflows. We learn how Microsoft co-designed this tool directly with staff nurses, nurse managers, and nurse executives across more than 10 health systems,  and why that collaboration is essential. We'll learn about Microsoft's vision for a three-stage AI future, from co-pilots to agents to a true hybrid workforce, and what it would mean for nurses to have the ability to delegate tasks the way physicians have long been able to do. Finally, we hear the deeply personal story behind Mary's mission,  from growing up in an immigrant household surrounded by nurse "aunties," to advocating for a voiceless patient at 4 am as a young nurse at Johns Hopkins, to now leading the technology that she believes will restore humanity and dignity to the very profession that shaped her.  Episode 131 features Dominic King, former surgeon and VP of Health at Microsoft AI, where his team builds and scales consumer health tools that see more than 50 million health-related sessions a day. In this conversation, we learn about Microsoft's partnership with Harvard Medical School and how it's working to ensure that the billions of health questions people ask AI every day are met with credible, clinically sound information. We also hear how he thinks about patient safety and trust in AI, and we'll get his candid take on what AI cannot replace, why clinicians must be central to scaling these tools beyond the pilot stage, and how he believes technology is the single biggest lever for making health systems sustainable in the face of growing global demand.      For more information on the podcast bundles, visit ANA's Innovation Website at https://www.nursingworld.org/practice-policy/innovation/education.    Have questions or feedback for the SEE YOU NOW team?  Future episode ideas? Contact us at hello@seeyounowpodcast.com.       

There is a palpable mix of excitement and anxiety about the latest impending wave of Artificial Intelligence. AI tools are being developed that will fundamentally impact our jobs, our relationships, our access to knowledge and creativity, our children's lives, and our planet. But for an industry like healthcare — where fax machines and pagers are common, where people struggle to find affordable care or adequate resources, and nurses are leaving the profession due to administrative burdens and moral distress — can AI be an answer?  In this two-part feature of our AI in Play series, where we explore AI's role in transforming healthcare, host Oriana Beaudet, Vice President of Innovation at the American Nurses Association, Credentialing Center, and Foundation, talks with a nurse and a clinician helping to shape the future of AI in healthcare for one of the largest technology companies in the world.   Episode 130 features nurse Mary Varghese-Presti, Corporate VP and COO of Microsoft Health and Life Sciences, whose team built Dragon Copilot, the first commercially available ambient AI solution purpose-built for nursing workflows. We learn how Microsoft co-designed this tool directly with staff nurses, nurse managers, and nurse executives across more than 10 health systems,  and why that collaboration is essential. We'll learn about Microsoft's vision for a three-stage AI future, from co-pilots to agents to a true hybrid workforce, and what it would mean for nurses to have the ability to delegate tasks the way physicians have long been able to do. Finally, we hear the deeply personal story behind Mary's mission,  from growing up in an immigrant household surrounded by nurse "aunties," to advocating for a voiceless patient at 4 am as a young nurse at Johns Hopkins, to now leading the technology that she believes will restore humanity and dignity to the very profession that shaped her.  Episode 131 features Dominic King, former surgeon and VP of Health at Microsoft AI, where his team builds and scales consumer health tools that see more than 50 million health-related sessions a day. In this conversation, we learn about Microsoft's partnership with Harvard Medical School and how it's working to ensure that the billions of health questions people ask AI every day are met with credible, clinically sound information. We also hear how he thinks about patient safety and trust in AI, and we'll get his candid take on what AI cannot replace, why clinicians must be central to scaling these tools beyond the pilot stage, and how he believes technology is the single biggest lever for making health systems sustainable in the face of growing global demand.    For more information on the podcast bundles, visit ANA's Innovation Website at https://www.nursingworld.org/practice-policy/innovation/education.    Have questions or feedback for the SEE YOU NOW team?  Future episode ideas? Contact us at hello@seeyounowpodcast.com. 

Send a textAI is accelerating drug development. Precision medicine is going mainstream. Rare disease innovation is reshaping pipelines.So what's really happening inside life sciences consulting right now?In this panel, leaders from Guidehouse, Clarkston Consulting, ClearView Healthcare Partners, and Roland Berger join Management Consulted for a direct, no-fluff look at where the industry is headed — and who wins in it.You'll hear:Where AI is actually creating value (not just headlines)How firms turn complex science into commercial decisionsWhat separates candidates who get offers from those who don'tEach firm is hiring now. Click here to connect with each panelist and learn more about the firms.Resources:Explore open roles at Clarkston, ClearView, Guidehouse, and Roland BergerJoin Black Belt for a personalized recruitment plan, expert-led coaching, and targeted digital resources to break into life sciences consultingJoin the last-ever Strategy Sprint (March 7-14)Build consulting experience, boost your resume, and make a real impact on this 1-week consulting project (the last-ever project) MBB Undergrad Timelines Are Moving UpApplication deadlines are the earliest we've ever seen; join Black Belt for a structured, MBB-led prep plan + coaching + resume editsEmployee Survival Guide®A Podcast only for employees. Mark shares information your employer does not want you knowListen on: Apple Podcasts SpotifyConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

Prefabrication works differently in highly regulated environments. In this episode of Prefab, Unfiltered, recorded live at Advancing Prefabrication, Todd Weyandt sits down with David O'Connell to explore how prefabrication, modular construction, and industrialized strategies perform inside life sciences, pharmaceutical manufacturing, and cleanroom construction. When time to market can mean tens of millions of dollars per day, construction strategy becomes a business-critical decision. But in regulated environments, every weld, inspection, and document must meet strict compliance standards. This conversation unpacks where prefabrication truly adds value in pharma and semiconductor projects, where full modular building approaches struggle, and why regulatory alignment is often the deciding factor. If you are involved in life sciences construction, cleanroom facilities, modular construction, or industrialized project delivery, this episode delivers a grounded and practical perspective.   You'll Learn Why full building modular often struggles in life sciences construction Where prefabrication works best in pharmaceutical and cleanroom environments How regulatory inspections shape prefab strategy Why partnering with agencies having jurisdiction is critical How time to market drives construction decisions in drug manufacturing The financial impact of schedule acceleration in regulated facilities   Meet Our Guest David O'Connell brings decades of experience across semiconductor, life sciences, and pharmaceutical construction. With a background shaped by multiple generations in construction and deep experience delivering highly technical facilities, he has worked at the intersection of prefabrication, regulatory compliance, and time-critical project delivery. His perspective bridges traditional construction methods and modern industrialized strategies, particularly in cleanroom environments and drug manufacturing facilities where documentation, inspection, and compliance are paramount.   Todd Takes Prefabrication Has to Respect Regulation. In pharmaceutical and life sciences construction, compliance is non-negotiable. Prefabrication does not remove regulatory scrutiny. It demands earlier coordination and stronger documentation. Inspectors and agencies must be brought in as partners, not treated as obstacles. Not Everything Should Be Modular. Full building modular has not consistently succeeded in highly regulated environments. Prefabrication often works best in repeatable components such as utility racks, panels, and cleanroom assemblies. Industrialized construction is not all or nothing. Strategic application matters. Time to Market Changes the Equation. In pharmaceutical manufacturing, delayed production can mean millions of dollars per day. That reality shifts the conversation from cost savings to schedule certainty and risk mitigation. Prefabrication becomes a strategic lever for accelerating capacity while maintaining compliance.   More Resources   Thanks for listening! Please be sure to leave a rating and/or review and follow up our social accounts. Bridging the Gap Website Bridging the Gap LinkedIn Bridging the Gap Instagram Bridging the Gap YouTube Todd's LinkedIn David's LinkedIn Verista's Website   Thank you to our sponsors! Graitec North America Graitec North America LinkedIn Autodesk's Website  

In this episode of Tiny Show and Tell Us, we talk about the crafty corvids that steal anti‑bird spikes to build chaotic, spiky nests and “Mitochondrial Eve” — the most recent common maternal ancestor of modern humans. Get ready for stories of sandwich‑stealing gulls, Deboki being held hostage by a peacock, and the Mitochondrial Eve/Y Chromosomal Adam romcom no one asked for.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jenny Opalinski has spent more than a decade inside hospitals where people lose the ability to speak, breathe, swallow, and sometimes survive. A medical speech language pathologist by training, she worked in ICU, neuro rehab, and long term acute care settings, including a Level 1 trauma center, where she watched clinicians absorb 10 to 15 traumatic events in a single shift and then get told to move the crash cart faster next time.That lived reality pushed her to co found The Wellness Shift, an advocacy and education platform focused on healthcare worker burnout, suicide, and assault. In this conversation, Opalinski walks through the moment that changed everything for her: standing in a hospital hallway listening to a family wail after a failed code, followed by a debrief that addressed logistics and ignored grief entirely.She also explains how that work led to Humanity Rx, her podcast about the human cost of medicine, and Dragon's Breath: Calming Tricks for Big Feelings, a children's book that translates evidence based breathing and regulation strategies into language kids can actually use. The episode covers moral injury, time scarcity, false wellness, respiratory muscle training, and why empathy keeps getting treated as an optional expense instead of clinical infrastructure.RELATED LINKSJenny Opalinski on LinkedInThe Wellness ShiftHumanity RxDragon's Breath: Calming Tricks for Big FeelingsAspire Respiratory ProductsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dimitri de Vreeze is CEO van DSM-Firmenich.***Volg Leaders in Life Sciences via de website.Volg Leaders in Life Sciences via LinkedIn.Bezoek www.henkjanout.nl voor meer informatie over de host.***Vragen, suggesties of feedback? Graag! Stuur een email naar: henkjan.out@me.com***Vind jij de Leaders in Life Sciences podcast leuk? Dan zouden we het enorm waarderen als je een recensie zou willen achterlaten op Apple Podcasts of een vijf sterren beoordeling zou willen geven op Spotify.Jouw steun betekent veel voor ons, omdat het anderen kan aanmoedigen om de podcast ook te gaan beluisteren. Heel erg bedankt!***Leaders in Life Sciences wordt mede mogelijk gemaakt door Pivot Park, Pedersen & Partners en Johnson & Johnson Innovative Medicine.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Monika Sumra, Ph.D., about how leadership, culture, and performance emerge from the environment and conditions inside an organization. Dr. Sumra, Founder and Managing Partner at Bunka, Inc., a management consulting firm and advisor to manufacturing-based organizations globally, explains how anthropology, CPIs, and rapid ethnography make culture measurable and operations faster, safer, and more reliable. Deploying a unique lens built on biosocial anthropology, she offers guidance on creating environments for sustainable performance in the complex life sciences industry. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Leadership quality and organisational culture are emerging as nearly equal priorities to compensation when professionals choose and stay with employers, according to the Cpl Salary Guide for Ireland 2026. The findings reveal a fundamental shift in talent priorities, as employees increasingly evaluate opportunities based on values, work environment, and leadership behaviours alongside financial rewards. The key findings from this year's report are as follows: While compensation and benefits remain the top priority at 35%, leadership and culture follow closely at 24% as the most important factor when choosing an employer. When examining both first and second most important factors combined, leadership and culture reaches 54% (24% first choice, 30% second choice), narrowing the gap with compensation and benefits at 62% (35% first choice, 27% second choice). Within the leadership and culture category, employees prioritise culture, values and ethics (27%), work environment (25%), and leadership behaviours (24%). Cpl's findings reinforce that leadership quality remains a critical driver of employee attrition. Flexible Working: The Essential Benefit Flexible working arrangements have evolved from a perk to a critical component of employee packages. After remuneration (32%), flexible working ranks as the second most important compensation and benefit factor at 26%. The research shows that 70% of employees now utilise some form of flexible working, with previous studies indicating that one in four candidates would not proceed with a job opportunity lacking flexibility. The predominant flexibility model is hybrid working (over 54%), typically with a 3/2 or 2/3 home/office split. However, next-generation arrangements are emerging, with 12% working fully remote and over 7% utilising compressed work weeks. Organisations offering structured, design-led flexible working strategies gain a significant competitive advantage, particularly when recruiting for high-skilled roles where talent is scarce. Work-Life Balance Takes Centre Stage Within employee experience priorities, work-life balance dominates at 40%, followed by meaningful and stimulating work at 21%. While not yet surpassing compensation in importance, work-life balance, when considered alongside flexible working, represents a core pillar of any successful talent strategy. AI Transitions from Specialist to Mainstream Capability Cpl's analysis found that, between 2022 and 2024, AI references in job titles and descriptions increased year-on-year, peaking in 2024. However, 2025 saw a correction as organisations moved beyond experimentation toward strategic implementation. AI demand remains concentrated in IT (55% of AI-related hiring), Life Sciences (17%), and Customer Service (13%). Business Intelligence has emerged as a distinct growth category since 2023, signalling a shift toward insight-led decision-making. Regulatory roles now account for 3% of AI positions, reflecting growing governance requirements. Cpl found that AI is becoming embedded within existing roles rather than creating new specialist positions. By 2024-2025, AI-related roles comprised just 3% of all jobs, yet within those roles, under 50% of job titles still referenced AI. References to AI in job descriptions have doubled compared to job titles, indicating that employers increasingly expect baseline AI literacy as a standard competency rather than a differentiator. Limited Company Growth Signals Workforce Evolution Ireland experienced near-record limited company incorporations in 2025, with approximately 25,000 new companies registered (a 5-6% increase on 2024). This growth reflects layoffs and slower permanent hiring for experienced professionals, prompting many to establish their own businesses providing specialist services across technology, life sciences, and financial services. This trend signals a structural shift toward self-employment, fractional leadership, and contingent workforce models, offering organisa...

Welcome to Health-e Law, Sheppard's podcast exploring the fascinating health tech topics and trends of the day. In this episode, partner and host Michael Orlando welcomes Eric Newsom, partner and Transactions lead of Sheppard's national Healthcare industry team, to discuss key takeaways from the 2026 J.P. Morgan Healthcare Conference and explore what growing AI adoption, shifting reimbursement models and evolving macroeconomics mean for M&A and strategic partnerships.   What we discuss in this episode: How the conference addressed the growing focus on AI-powered healthcare platforms. The key factors driving adoption of AI technologies across the healthcare industry. How providers and payers are adjusting their M&A and joint‑venture strategies amid shifting reimbursement models and evolving macroeconomic pressures. The top three priorities for healthcare leaders when advancing AI adoption and structuring strategic partnerships. Topics not covered at the conference that Eric would have liked to learn more about.   About Eric Newsom Eric Newsom is a partner in the Corporate practice group in Sheppard's San Francisco office and serves as Transactions Lead of the firm's national Healthcare industry team. Eric's nationwide practice focuses on mergers and acquisitions, strategic joint ventures, corporate reorganizations, private equity and venture capital transactions, and corporate governance and compliance matters. Eric has represented buyers, sellers, investors, and intermediaries in numerous business combinations, buyouts, and investment transactions, with particular emphasis on the healthcare industry. In his healthcare and health technology practice, Eric advises on mergers, acquisitions, affiliations, comprehensive corporate reorganizations, multi-channel joint ventures, and private equity investment and disposition transactions. His experience spans for-profit, nonprofit, and government-owned hospital and provider systems; academic medical centers; health plans; physician groups; ambulatory and specialty service providers; and startup and growth-stage companies in the healthcare information technology sector.   About Michael Orlando Michael Orlando is a partner in Sheppard's San Diego (Del Mar) office. He is team leader of the firm's Technology Transactions team, a member of the Life Sciences, Healthcare and Artificial Intelligence teams, and co-leader of the firm's Digital Health & Innovation team. Michael has more than 20 years of experience advising health technology companies, insurers, healthcare systems and providers, academic medical centers and research institutions, medical device manufacturers, and pharmaceutical and wellness companies on intellectual property and business transactions in key strategic areas, including EHR systems procurement and integration, telehealth, mobile health applications, clinical decision support technologies, artificial intelligence, data use, wearable devices, remote patient monitoring, and other medical devices, research and collaborations, patent licenses, software licenses, joint ventures, mergers and acquisitions, revenue cycle management, and other outsourcing transactions.    Michael founded a software-as-a-service company before entering private practice and completed an in-house secondment at a publicly traded biotechnology company, an experience that informs his practical and business-focused approach to client engagements.   Contact Info Eric Newsom Michael Orlando    Thank you for listening! Don't forget to SUBSCRIBE to the show to receive new episodes delivered straight to your podcast player every month. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show on Apple Podcasts, Amazon Music, or Spotify. It helps other listeners find this show. This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.

The decision to bootstrap a business or raise venture capital is not just financial. It is physics. You are choosing which system to operate within, which rules will govern your company, and whose incentives will shape your options at every inflection point. Rob Taylor has lived both realities. He spent years building venture-backed companies, raising millions in institutional capital. His brother Chris bootstrapped a company for 20 years and owned nearly 100% at exit. They sold their companies the same year and ended up in roughly the same place financially. The question is what do you optimize for, and the nature of that question is changing daily in the age of AI. Recorded live at Red Fridge Society.The Agenda0:00 Intro + Defining Bootstrap vs. VC 7:23 Is Your Business VC-Backable 11:54 The Ecosystem You Gain with Institutional Capital 15:03 The Ownership Curve 20:36 Control and Governance 26:24 Disruption in the AI Era 32:41 How Fund Size Shapes Investment Behavior 37:43 The Bootstrap-VC Overlap 40:54 Choosing Your Partner 45:14 The Incremental Approach to RaisingGuest LinksRob Taylor: LinkedIn, Silverton PartnersRed Fridge Society -------------------Austin Next Links: Website, X/Twitter, YouTube, LinkedInEcosystem Metacognition Substack

AI-first is table stakes; instead, outcomes-first delivery in collaboration with a partner ecosystem unlocks growth, access, and resilience. Key discussion points include:AI-first is no longer differentiating, but outcomes are. Most providers claim AI-first, but the real shift is to outcomes-first delivery tied to better health, better experience, lower cost, and equity. The old delivery playbook won't survive the revenue headwind and patent cliff era. Life science enterprises need a new operating model, Services-as-Software, to rewire discovery-to-commercial and drive measurable impact. Winning suppliers become growth partners, not just capacity providers. The next wave is precision medicine, real-world evidence, global resilient supply chains, and continuous patient engagement; vendors that bring IP/platforms and ecosystem innovation move from Horizon 2 toward Horizon 3.Listen to this conversation and review our perspective at https://www.hfsresearch.com/research/life-sciences-suppliers-black-hole/Read the HFS Horizons Report on Life Sciences Service Providers, 2025: https://www.hfsresearch.com/research/hfs-horizons-life-sciences-service-providers-2025/

As part of the February issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews David Halpin (University of Exeter Medical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK) about his Viewpoint editorial on a shared vision from the Global Initiative for Chronic Obstructive Lung Disease and the Global Initiative for Asthma of how to address the global challenges of COPD and asthma, published in this issue of the ERJ (https://doi.org/10.1183/13993003.02244-2025). Cite this podcast as: ERJ Podcast February 2026: Addressing the global challenges of COPD and asthma. Eur Respir J 2026; 67: 26E6702 [https://doi.org/10.1183/13993003.E6702-2026].

“Let's inspect what we expect.” What a powerful statement. If we expect cost transparency, let's inspect what those costs have been to date. If we expect freedom of choice, let's evaluate how that has worked for employees up to this point. And let's expect an “and” approach instead of an “or” approach. As I say often these days, the devil is in the details, so it only makes sense that we put some energy and effort into inspecting what those details are and have been so we can expect what they will be in the future. That's exactly the goal and role of today's guest.  Jeff Bak is the President of Imagine360, whose mission is to reduce health plan costs for  employers, employees and their families. He has three decades of experience in managing and growing healthcare services companies. Prior to Imagine360, Jeff served as the global practice leader of the Health, Life Sciences & Business Process Outsourcing (BPO) division for Wipro Limited, and was the president and CEO of HealthPlan Holdings (HPH)—a leading healthcare solutions business.

We are excited to begin In the Public Interest's sixth season with the introduction of our new cohost Jekkie Kim. Jekkie is a corporate partner in WilmerHale's Palo Alto office who focuses on life sciences technology and transactions and works closely with founders and emerging companies to support every stage of their commercial development. In conversation with her co-host Felicia Ellsworth, Jekkie shares insights into the life sciences industry, drawing on her varied career and experience both as a practicing attorney and education as a doctor. She discusses how she leverages her medical background in her current practice, allowing her to effectively serve clients and move quickly to match the fast-moving innovations coming out of Silicon Valley. She and Felicia also share advice for law students and early-career attorneys, speaking to the importance of mentorship and how to explore potential areas of focus.

For over a thousand years, humans have been harnessing wind energy. It may have begun with small, grain‑grinding windmills in ancient Persia, but today you might spot Hoover‑Dam‑sized offshore turbines as you drive along the east coast. How did we get here? In this episode of Tiny Matters, we explore the first electric wind turbines built in the late 1800s, how government policies in the 1970s and '80s shaped the modern wind industry, and why giant offshore wind farms are suddenly in the news. We also clear up misinformation stemming from a Hollywood blockbuster as well as what we know about the impact of wind farms on whales, birds and bats.In this episode, we explore the surprising origins and evolution of one of modern medicine's most important tools: the clinical trial. We follow the development of experimental design across centuries to modern day randomized controlled trials and the debates about their limitations, trying to answer the question, “How do we know whether a treatment truly works?”Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sarah Gromko and Matthew Zachary go back to SUNY Binghamton in the early 1990s, when they were barely 19 and living inside rehearsal rooms. She starred in campus musical theater productions. He served as pianist and music director for many of those shows and played rehearsal piano for the THEA101 repertory company. This episode reunites two former theater nerds who grew up and took very different paths through art, illness, and work that still circles the same truth.Gromko trained as a singer and composer, studied film scoring at Berklee College of Music, worked in New York and New Orleans, then moved into healthcare as a speech language pathologist and recognized vocologist. She explains aphasia, apraxia, dysarthria, and dysphagia with clarity earned from the clinic. She recounts helping a 16 year old gunshot survivor in New Orleans speak again using Melodic Intonation Therapy. The conversation covers voice banking for ALS, gender affirming voice care, and the damage caused when medicine confuses speech loss with intelligence loss. The result feels like an epic reunion powered by 1990s nostalgia and sharpened by decades of lived consequence.RELATED LINKSSarah GromkoGramco VoiceMelodic Intonation TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to the Podcast of Southwest Bible Fellowship in Tempe, Arizona. WHO ARE WE? • We are a group of people who are committed to living the grace life as set forth by the apostle of the Gentiles, the Apostle Paul. • We come together to study our Bibles, and yes, we believe we have God's perfect Word in the King James Bible. It and it alone is our final authority in all matters of faith and practice! • We do not come together and study our Bibles for the intent of being smarter than others. We understand that knowledge for the sake of knowledge is purely vain and serves no Godly purpose. • We do come together and study our Bibles for the intent of knowing our Lord Jesus Christ and the power of His resurrection. (Philippians 3:10) • We do come together and study our Bibles to understand that we have been crucified with Christ; nevertheless we live; yet not us, but Christ liveth in us: and the life which we now live in the flesh, we live by the faith of the Son of God, who loved us and gave himself for us. (Galatians 2:20) • We do come together and study our Bibles to understand that because Jesus Christ shed His blood for us and we should not live for ourselves but for Him, who died for us and rose again. (2 Cor. 5:15) • We do not claim to have attained to these lofty goals, but we press toward the mark of the prize of the high calling of God in Christ Jesus. (Philippians 3:14) You can donate to this ministry through www.butnow.org and the PayPal button on the homepage.

The unprecedented rapid pace of AI and tech innovation has transformed healthcare and life science organizations. With many new answers however come lots of new questions about how to ensure continuous reinforcement of deep, hands-on knowledge of the science and detailed steps behind the art of diagnosis or steps in an experiment, and to enable the best talent in healthcare truly express itself despite the real-world struggles to find the resources they truly need and fill the job positions where their innovation can flourish.At the 2025 Medical Innovation Olympics, Tim Mikhelashvili (CEO, Amedea Pharma, Host #MIO2025) brought together an expert panel of executives in Human Resources, Life Sciences, Marketing, Founders and Investors (Kim Mack, Founder & Principal, HR Reinforced; Christina Smith, Founder, Neo HR Consulting Group; Christopher Piedmonte, Managing Director, NeoTerra Capital, and Bart Zoni, SVP Innovation & Product, Woven Health Collective) addressed a sensitive question on top of millions of people's minds in healthcare - in an AI-powered talent market, how do we hire, reward, and retain teams where deep scientific judgment and technical execution must win together—every single day? This session focused on the underlying human factors behind both layering and rewarding the best talent across science and tech in healthcare. Speakers shared practical solutions to build a strong culture that rewards both as leaders, hire, interview, onboard teams, as well as distinguish talent through innovative methods such as video submissions of candidates' CV's or work samples. 0:00 Episode Highlight 1 - Move from "No But to Yes If" in Medicine0:49 Episode Highlight 2 - Fusion of Science & Tech1:34 Opening Remarks - Lots of Talent - Few Ways to Express It3:07 Expert Panelist Introductions5:41 How do you reward Science versus Tech in Life Sciences?10:11 Hiring True Talent in the Age of AI crafted Resumes16:38 Onboarding & Retaining Best Talent 17:05 What the Tech Industry should learn from Science?19:24 What Life Science should learn from Tech20:17 Driving Quality Science despite more Informal Training21:05 Building Cross-Functional Pods across Science & Tech26:28 Q&A: How do you balance and upskill Medical Talent?27:57 Q&A: How do you work around AI to hire best talent?30:50 Q&A: Value of Video Submissions of CVs/Resumes31:42 Q&A: Work Sample or Task Completions in Interviews32:27 Final Thoughts - Optimism about Rewarding Best Talent

Send a textMike Romance has spent nearly two decades operating at the intersection of manufacturing engineering, automation, validation, and operations leadership within the life-sciences ecosystem. His career spans startups and established organizations alike, with hands-on experience taking products from early development through GMP-ready, high-volume production. Across roles in process development, automation, quality systems, and manufacturing strategy, Mike has built a reputation for combining technical rigor with pragmatic execution.Most recently at Quantum-Si, Mike played a central role in scaling operations to support the commercialization of the Platinum protein sequencing platform while laying the groundwork for next-generation technologies like the Proteus platform. Working within a lean and highly agile leadership team, he helped establish scalable manufacturing foundations spanning CM-managed instrument supply, internal reagent kit production, and advanced silicon-based consumables—while navigating the realities of fast-moving product roadmaps and constrained resources.Earlier in his career, Mike held engineering and leadership roles at organizations including Illumina, Dexcom, GenMark Diagnostics, Truvian, and Encodia. Along the way, he's led pilot-line development, automation strategy, equipment qualification, validation programs, and process controls—often in environments where the path forward wasn't clearly defined.What sets Mike apart is not just his command of acronyms—GAMP, CQV, QbD, DFSS, FMEA—but his philosophy that systems only work when people do. He actively practices emotionally intelligent leadership, prioritizing trust, clarity, and psychological safety while still holding teams to high technical and operational standards. As Mike explores his next chapter, this conversation focuses on the lessons he's learned building resilient manufacturing systems—and the kind of organizations where he believes he can make the biggest impact next.LINKS:Guest LinkedIn: https://www.linkedin.com/in/mikeromance/Aaron Moncur, host The Wave is  a place for engineers to actively learn, share ideas, and engage with people doing similar work. Learn more at thewave.engineer Subscribe to the show to get notified so you don't miss new episodes every Friday.The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us Watch the show on YouTube: www.youtube.com/@TeamPipelineus

We're doubling down on our YouTube content, so if you want to watch this video instead of listening to it, you can watch it on our channel here: https://www.youtube.com/@SuccessionBioAbout SuccessionSuccession helps founders and sales teams close more deals with biotech and pharma. We partner with our clients to run modern lead generation campaigns, up-skill their team through personalized sales training, and build AI workflows using cutting-edge tools and technology.Ready to take your go-to-market to the next level?

In this episode of Tiny Show and Tell Us, we explore a listener's tip about a new source of tire rubber — the Russian dandelion — and the science behind what makes it such an incredible and sustainable source of natural latex rubber. Then we answer a listener's question about a vaccine for fentanyl that will stop the drug from reaching the brain, preventing overdose.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Matt Hampton and Dr Tom Ingegno came into my world the way the best guests always do. They found me first. They pulled me onto their Irreverent Health Podcast, a show that blends medicine, curiosity, and unapologetic nonsense the same way Gen X kids blended Saturday morning cartoons with nuclear-war anxiety. We recorded together, we went off the rails together, and by the end I told them the rule. If you ever come to New York, you sit in my studio. No exceptions.They showed up. They took the hot seat. They told Alexa to shut up. They joked about Postmates. They compared bifocals before I even hit record. From there it turned into a full blown eighties time machine powered by weed policy, AI diagnostics, acupuncture philosophy, art school trauma, cannabis data science, paranormal detours, and the kind of deep cut pop culture references only Gen X survivors can decode.Matt builds AI systems. Tom heals people with needles and a lifetime of East Asian medicine. Together they make healthcare funny without pretending it works. They remind you that curiosity carries weight when the system collapses under its own stupidity.This episode is a reunion of three loudmouths raised on Atari, late night cable, and the hard lesson that you either tell the truth or get flattened by it. Go subscribe to Irreverent Health. These guys earned it.RELATED LINKS• Irreverent Health Podcast• Matt Hampton – Consilium Institute• Envoy Design• Dr. Tom Ingegno – Charm City Integrative Health• The Cupping Book• You Got Sick—Now What?• Matt Hampton on LinkedIn• Dr. Tom Ingegno on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Christine Moundas, Health Care and Data Partner at Ropes & Gray LLP and Co-Head of the firm's Digital Health Initiative, discusses the new landscape of state consumer privacy laws and how life sciences and medical device companies can comply with these new requirements. Sponsored by Ropes & Gray.Watch this episode: https://www.youtube.com/watch?v=wGUy4Bs72t4Learn more about Ropes & Gray: https://www.ropesgray.com/enEssential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Comprehensive members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.

Healthcare marketers are having to navigate massive shifts across the industry, including shrinking ROI timelines and increasingly complex buyer committees. In this episode, I'm joined by my two colleagues and fellow Health Launchpad principals, Mark Erwich and Matthew Piette, for a conversation about what it means to be a marketing leader in healthcare right now. We explore how the industry is moving from the traditional triple aim toward what we call the quintuple squeeze, where providers face intense pressure from regulatory changes, margin constraints, and severe staffing shortages.We provide a deep dive into how both health tech and biotech firms can adapt their strategies to remain defensible in front of CFOs. We also share our perspectives on the practical use of AI as an efficiency tool and why focusing on risk reduction may be more important than selling growth in the coming year.Key Topics Covered"(00:00:00) Introduction""(00:09:00) Big Drivers in Healthcare Technology""(00:13:00) The Quintuple Squeeze""(00:15:00) Challenges in Biotech and Life Sciences""(00:16:00) Pressure on Marketing Leaders""(00:17:00) Shortened Planning Horizons""(00:19:00) Biotech Marketing Constraints""(00:21:00) AI: Friend or Foe?""(00:26:00) Impact on Marketing Budgets""(00:30:00) Justifying Your Marketing Budget""(00:34:00) Stop Doing This to Survive""(00:37:00) Five Key Takeaways"If you are interested in discussing this or any other topic, let's have a chat.  Reach out to me directly to schedule a no-obligation discussion. This isn't a sales call, but rather an opportunity to talk through your questions and challenges.Follow me on LinkedIn.Subscribe to The Healthtech Marketing Show on Spotify or watch us on YouTube for more insights into marketing, AI, ABM, buyer journeys, and beyond!Thank you to our presenting sponsor, HealthcareNOW, 24/7 expert shows, interviews, and podcasts, powering healthcare leaders with innovation, policy, and strategy insights.

Welcome to Health-e Law, Sheppard's podcast exploring the fascinating health tech topics and trends of the day. In this episode, partner and host Michael Orlando welcomes Amanda Zablocki, co-leader of Sheppard's Healthcare industry team, to explore key insights from the 2026 J.P. Morgan Healthcare Conference and discuss how digital innovation is transforming the healthcare M&A landscape What We Discuss in This Episode: How did buzzwords like AI and innovation shape conversations at this year's J.P. Morgan Healthcare Conference? What role does technology play in healthcare transactions? How is AI driving the next wave of consolidation among hospitals, health systems and health plans? What are the challenges and opportunities in integrating technology platforms during mergers and acquisitions? How does technology leadership influence whether an organization becomes a buyer, partner or target, and why is it critical to involve technology leaders early in the deal-making process? What is the impact of data assets, analytics platforms and AI-driven tools on healthcare transactions? How can organizations balance the cost of technology with their mission to serve patients and communities? What legal and regulatory considerations should healthcare organizations prioritize when adopting new technologies?   About Amanda Zablocki Amanda Zablocki is a partner in the Corporate practice group in Sheppard's New York office and co-leader of the firm's Healthcare Industry team. A trusted legal and strategic advisor to healthcare organizations nationwide, she helps them to achieve their mission and goals while navigating a dynamic regulatory landscape. Large-scale, strategic transactions—mergers and acquisitions, joint ventures and strategic partnerships, and corporate reorganizations—are at the center of Amanda's practice. With extensive industry knowledge, a deep understanding of the key drivers and levers for success, and broad experience navigating the complex healthcare regulatory landscape, she helps clients close high-impact deals that transform healthcare. Amanda's clients include health plans and health insurers, hospital systems, academic medical centers, digital health and healthcare technology companies, pharmaceutical and life sciences companies, rare disease organizations, physician practices, management services organizations, value-based care organizations, and 501(c)(3) organizations. Having begun her career in commercial litigation, she brings a litigator's eye to managing risk in connection with disputes and advocating her clients' positions. Amanda co-founded Sheppard's Women in Healthcare Leadership Collaborative, an exclusive initiative that provides support to women professionals in the healthcare and life sciences industries. She is also co-founder and a board member of Hyper IgM Foundation, an organization committed to improving the treatment, quality of life and long-term outlook for children and adults living with Hyper IgM.   About Michael Orlando Michael Orlando is a partner in Sheppard's San Diego (Del Mar) office. He is team leader of the firm's Technology Transactions team, a member of the Life Sciences, Healthcare and Artificial Intelligence teams, and co-leader of the firm's Digital Health team. Michael has more than 20 years of experience advising health technology companies, insurers, healthcare systems and providers, academic medical centers and research institutions, medical device manufacturers, and pharmaceutical and wellness companies on intellectual property and business transactions in key strategic areas, including EHR systems procurement and integration, telehealth, wearable devices, remote patient monitoring, mobile health applications, clinical decision support technologies, artificial intelligence, data use, research and collaborations, patent licenses, software licenses, joint ventures, mergers and acquisitions, revenue cycle management, and other outsourcing transactions.  Before entering private practice, Michael founded a software-as-a-service company and completed an in-house secondment at a publicly traded biotechnology company, an experience that informs his practical and business-focused approach to client engagements.   Contact Info Amanda Zablocki Michael Orlando   Resources Women in Leadership Healthcare Collaborative (WHLC)   Thank you for listening! Don't forget to SUBSCRIBE to the show to receive new episodes delivered straight to your podcast player every month. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show on Apple Podcasts, Amazon Music, or Spotify. It helps other listeners find this show. This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.

Welcome to the Podcast of Southwest Bible Fellowship in Tempe, Arizona. WHO ARE WE? • We are a group of people who are committed to living the grace life as set forth by the apostle of the Gentiles, the Apostle Paul. • We come together to study our Bibles, and yes, we believe we have God's perfect Word in the King James Bible. It and it alone is our final authority in all matters of faith and practice! • We do not come together and study our Bibles for the intent of being smarter than others. We understand that knowledge for the sake of knowledge is purely vain and serves no Godly purpose. • We do come together and study our Bibles for the intent of knowing our Lord Jesus Christ and the power of His resurrection. (Philippians 3:10) • We do come together and study our Bibles to understand that we have been crucified with Christ; nevertheless we live; yet not us, but Christ liveth in us: and the life which we now live in the flesh, we live by the faith of the Son of God, who loved us and gave himself for us. (Galatians 2:20) • We do come together and study our Bibles to understand that because Jesus Christ shed His blood for us and we should not live for ourselves but for Him, who died for us and rose again. (2 Cor. 5:15) • We do not claim to have attained to these lofty goals, but we press toward the mark of the prize of the high calling of God in Christ Jesus. (Philippians 3:14) You can donate to this ministry through www.butnow.org and the PayPal button on the homepage.

In this special ProveIt edition of Manufacturing Hub, Vlad Romanoff and Dave Griffith sit down with Amy Williams from Skellig Automation to unpack Enterprise C, a life sciences virtual factory built to look and feel like the reality inside many regulated facilities today. If you work around batch processes, compliance, historian projects, electronic batch records, or industrial data architecture, this conversation is a practical walkthrough of what it actually takes to turn raw signals into a story you can defend, improve, and scale.Amy has spent years working exclusively in life sciences manufacturing, starting deep in DeltaV automation for batch pharma and moving into digital transformation projects that focus on open architectures, modern data pipelines, and real operational outcomes. In this episode, she explains what Enterprise C is simulating, why it was designed as an Industry 3.0 style biotech startup, and what kind of data and documentation a vendor would have to wrestle with in the real world. The factory is producing a fictional enzyme using a fed batch fermentation process, and the UNS publishes realistic one second resolution batch data across four pieces of single use equipment including a mixer, a bioreactor, a chromatography skid, and a TFF skid.One of the most valuable parts of this episode is the reminder that data sitting in an MQTT broker is not inherently valuable. The value comes when the data is contextualized enough that different teams can use it without tribal knowledge, and when the resulting traceability helps you answer the questions that matter in life sciences. What happened during the batch, what changed compared to previous runs, what went out of spec, what documentation proves compliance, and what you should do next time to avoid losing a batch that can cost millions. Amy also explains why Enterprise C intentionally includes uncontextualized tags and paper files, because that is exactly where many facilities still are. The hard part is not connecting a sensor, the hard part is governance, agreement, and building a model that humans actually follow.You will also hear the crew dig into Smart Manufacturing Profiles and why standardizing information models is one of the clearest paths toward true interoperability. If you are tired of every site, every integrator, and every project reinventing the same pump, valve, and equipment model from scratch, this is the kind of conversation that helps frame why that problem keeps repeating and what might finally reduce it. The ProveIt format forces the questions that most conferences avoid, including what problem was solved, how it was done, how long it took, and what it cost. That is exactly why this conference has become a magnet for practitioners who care about the difference between a demo and a deployable solution.About the hostsVlad Romanoff is an industrial automation and manufacturing systems expert and the founder of Joltek. He has over a decade of experience modernizing control systems, data infrastructure, and plant operations across regulated and high throughput manufacturing environments.Dave Griffith is the cohost of Manufacturing Hub and a long time practitioner in industrial automation and manufacturing technology, focused on practical deployment and what actually works on the plant floor.About the guestAmy Williams works with Skellig Automation and has spent years in life sciences manufacturing, from DeltaV batch automation to digital transformation initiatives that focus on open architectures, data contextualization, and scalable modernization strategies.Timestamps 00:00 ProveIt edition intro and why this month is technology modernization 01:40 Who is Amy Williams and why Enterprise C matters this year 02:10 Amy's background in life sciences, DeltaV, and digital transformation 03:30 Unified Namespace explained in plain language for life sciences 05:10 What Enterprise C publishes and what you will see in the MQTT broker 07:10 Why UNS in life sciences is about use cases, not buzzwords 10:10 Smart Manufacturing Profiles and reducing data model reinvention 11:10 What outcomes to expect including compliance and golden batch analysis 12:10 Enterprise C process overview from mixer to bioreactor to downstream 14:10 Bioreactor instrumentation and what operators still do manually 19:40 Why Enterprise C data is intentionally not contextualized 22:10 The real work of mapping signals to compliance stories and governance 25:10 What SM Profiles enable and why schema matters before data arrives 31:30 Why cost and time questions change everything at ProveIt 36:10 Cell counter files, batch records, and paper driven reality in many sites 45:10 What life sciences attendees should ask during Q and A 58:30 Vendors the team is excited to see and why non traditional players matter 01:02:20 Where to find Skellig at the conference and what they are bringingReferences and links mentioned Skellig Automation https://www.skellig.com/ProveIt Conference https://www.proveitconference.com/CESMII Smart Manufacturing Profiles and Marketplace https://www.cesmii.org/technology/sm-profiles/ https://marketplace.cesmii.net/Joltek resources related to this episode Mastering Unified Namespace https://www.joltek.com/blog/mastering-unified-namespace-uns-a-guide-to-data-driven-manufacturing-transformation Ultimate Guide to MQTT in Manufacturing https://www.joltek.com/blog/ultimate-guide-mqtt-manufacturingSubscribe and follow Manufacturing Hub for more conversations on technology modernization, UNS architecture, MQTT, industrial data systems, and how real factories actually evolve when the goal is uptime, compliance, and measurable outcomes.

Talent mobility, specialized roles, scarce market data and other competitive pressures create unusually complex pay transparency challenges for life sciences companies. Jackson Lewis' Life Sciences Group Co-leader Peggy Strange joins podcast host Laura Mitchell to discuss how moving from pushback to preparation can address benchmarking gaps, confidentiality concerns and exception requests to protect IP and trade secrets while promoting pay transparency and pay equity compliance. 

******Support the channel******Patreon: https://www.patreon.com/thedissenterPayPal: paypal.me/thedissenterPayPal Subscription 1 Dollar: https://tinyurl.com/yb3acuuyPayPal Subscription 3 Dollars: https://tinyurl.com/ybn6bg9lPayPal Subscription 5 Dollars: https://tinyurl.com/ycmr9gpzPayPal Subscription 10 Dollars: https://tinyurl.com/y9r3fc9mPayPal Subscription 20 Dollars: https://tinyurl.com/y95uvkao ******Follow me on******Website: https://www.thedissenter.net/The Dissenter Goodreads list: https://shorturl.at/7BMoBFacebook: https://www.facebook.com/thedissenteryt/Twitter: https://x.com/TheDissenterYT This show is sponsored by Enlites, Learning & Development done differently. Check the website here: http://enlites.com/ Dr. Coleen Murphy is James A. Elkins Jr. Professor in the Life Sciences, and Professor of Molecular Biology and Director of the Lewis-Sigler Institute for Integrative Genomics at Princeton University. She is the author of How We Age: The Science of Longevity. In this episode, we focus on How We Age. We discuss the science of aging, what we can learn from it, why we age, and what we can learn from animal models and centenarians. We also talk about longevity pathways, and transgenerational effects. We discuss whether intermittent fasting works. We talk about the role of DNA repair and cell replacement. We discuss whether the gut microbiome plays a role in aging. Finally, we talk about the current state of longevity biotech, and how to approach new developments.--A HUGE THANK YOU TO MY PATRONS/SUPPORTERS: PER HELGE LARSEN, JERRY MULLER, BERNARDO SEIXAS, ADAM KESSEL, MATTHEW WHITINGBIRD, ARNAUD WOLFF, TIM HOLLOSY, HENRIK AHLENIUS, ROBERT WINDHAGER, RUI INACIO, ZOOP, MARCO NEVES, COLIN HOLBROOK, PHIL KAVANAGH, SAMUEL ANDREEFF, FRANCIS FORDE, TIAGO NUNES, FERGAL CUSSEN, HAL HERZOG, NUNO MACHADO, JONATHAN LEIBRANT, JOÃO LINHARES, STANTON T, SAMUEL CORREA, ERIK HAINES, MARK SMITH, JOÃO EIRA, TOM HUMMEL, SARDUS FRANCE, DAVID SLOAN WILSON, YACILA DEZA-ARAUJO, ROMAIN ROCH, YANICK PUNTER, CHARLOTTE BLEASE, NICOLE BARBARO, ADAM HUNT, PAWEL OSTASZEWSKI, NELLEKE BAK, GUY MADISON, GARY G HELLMANN, SAIMA AFZAL, ADRIAN JAEGGI, PAULO TOLENTINO, JOÃO BARBOSA, JULIAN PRICE, HEDIN BRØNNER, FRANCA BORTOLOTTI, GABRIEL PONS CORTÈS, URSULA LITZCKE, SCOTT, ZACHARY FISH, TIM DUFFY, SUNNY SMITH, JON WISMAN, WILLIAM BUCKNER, LUKE GLOWACKI, GEORGIOS THEOPHANOUS, CHRIS WILLIAMSON, PETER WOLOSZYN, DAVID WILLIAMS, DIOGO COSTA, ALEX CHAU, CORALIE CHEVALLIER, BANGALORE ATHEISTS, LARRY D. LEE JR., OLD HERRINGBONE, MICHAEL BAILEY, DAN SPERBER, ROBERT GRESSIS, JEFF MCMAHAN, JAKE ZUEHL, MARK CAMPBELL, TOMAS DAUBNER, LUKE NISSEN, KIMBERLY JOHNSON, JESSICA NOWICKI, LINDA BRANDIN, VALENTIN STEINMANN, ALEXANDER HUBBARD, BR, JONAS HERTNER, URSULA GOODENOUGH, DAVID PINSOF, SEAN NELSON, MIKE LAVIGNE, JOS KNECHT, LUCY, MANVIR SINGH, PETRA WEIMANN, CAROLA FEEST, MAURO JÚNIOR, 航 豊川, TONY BARRETT, NIKOLAI VISHNEVSKY, STEVEN GANGESTAD, TED FARRIS, HUGO B., JAMES, JORDAN MANSFIELD, CHARLOTTE ALLEN, PETER STOYKO, DAVID TONNER, LEE BECK, PATRICK DALTON-HOLMES, NICK KRASNEY, RACHEL ZAK, DENNIS XAVIER, CHINMAYA BHAT, AND RHYS!A SPECIAL THANKS TO MY PRODUCERS, YZAR WEHBE, JIM FRANK, ŁUKASZ STAFINIAK, TOM VANEGDOM, BERNARD HUGUENEY, CURTIS DIXON, BENEDIKT MUELLER, THOMAS TRUMBLE, KATHRINE AND PATRICK TOBIN, JONCARLO MONTENEGRO, NICK GOLDEN, CHRISTINE GLASS, IGOR NIKIFOROVSKI, AND PER KRAULIS!AND TO MY EXECUTIVE PRODUCERS, MATTHEW LAVENDER,SERGIU CODREANU, AND GREGORY HASTINGS!

In this episode of The Steward Chair, Maria Thacker Goethe, President and CEO of Georgia Life Sciences, shares her journey of transitioning from a dedicated "number two" to leading a massive ecosystem through a global pandemic. We explore how a commitment to mission and the guidance of mentors drives meaningful, long-term success even when the original plan is upended. We discuss the critical role of a connector in the life sciences sector, the importance of "work-life harmony" over balance, and why true stewardship means preparing the next generation to lead. This conversation provides actionable takeaways for leaders committed to stewardship, integrity, and impact. Key Takeaways Purpose Over Tactics: In times of crisis, your "North Star" must be your organizational purpose, allowing your tactics to remain nimble and adaptive. The Responsibility of Mentorship: Leadership is a societal responsibility; investing time in the next generation is essential because no leader is "here forever". Embracing "Ready Enough": You don’t have to feel fully ready to step into a leadership seat; surrounding yourself with a community that believes in you is the key to moving forward through fear. Resources Mentioned Visit https://www.galifesciences.org/ Follow Maria on LinkedIn at https://www.linkedin.com/in/mariathacker/ Join the Georgia Life Sciences mailing list at: https://www.galifesciences.org/join-the-mailing-list Join the ConversationThe Steward Chair is about equipping and inspiring business leaders to build organizations that stand the test of time. If this episode resonated with you, share your biggest takeaway and tag us on LinkedIn @ChatWithLeaders. Elevate your podcast, company meeting, or industry event strategies to better engage stakeholders and drive meaningful growth! Visit ChatWithLeaders.com to learn more about how we can help.See omnystudio.com/listener for privacy information.

In 1599, a family in a small French town claimed that their daughter was possessed by a demon called Beelzebub and, despite daily exorcisms, the demon possessing this woman was staying put. So France's Henri IV set up a royal commission that would try something a little different. The woman would still receive exorcisms, complete with the normal exorcism accoutrements, but with a catch. The priest wouldn't actually be Catholic, the water in the vessel would be ordinary water, and the Latin used wouldn't be religious — it would be from Virgil's famous poem Aeneid. That's because this wasn't actually an exorcism. It was an experiment built on a deceptively simple tool that scientists and doctors still use today to study new medical treatments: a placebo.In this episode, we explore the surprising origins and evolution of one of modern medicine's most important tools: the clinical trial. We follow the development of experimental design across centuries to modern day randomized controlled trials and the debates about their limitations, trying to answer the question, “How do we know whether a treatment truly works?”Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Bill Thach has had 9 lines of treatment, over 1,000 doses of chemo, and more scans than an airport. He runs ultramarathons for fun. He jokes about being his own Porta Potty. He became a father, then got cancer while his daughter was 5 months old. Today she is 8. He hides the worst of it so she can believe he stands strong, even when he knows that hiding has a cost.We talk about the illusion of strength, what it means to look fine when your body is falling apart, and how a random postcard in an MD Anderson waiting room led him to Man Up to Cancer, where he now leads Diversity and AYA Engagement. Fatherhood. Rage. Sex. Denial. Humor. Survival. All that and why the words good morning can act like a lifeline.RELATED LINKSFight Colorectal CancerCURE TodayINCA AllianceMan Up to CancerWeeViewsYouTubeLinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Most biotech breakthroughs don't fail in the lab.They fail when science meets manufacturing reality.And by the time this bottleneck appears, tens of millions are already sunk.This episode examines the most under-discussed failure point in modern biotech: the gap between scientific discovery and scalable, usable healthcare solutions.While science has never been stronger—and big pharma excels at market access—companies that can translate breakthrough biology into industrialized medicines remain rare. Manufacturing, regulation, clinical design, usability for patients and physicians, and global scalability still form a narrow bottleneck where most value is lost.In this conversation, Björn Cochlovius, CEO of Eleva, explains why so many promising biologics fail late—and how Eleva deliberately built a platform designed not to replace existing systems, but to rescue projects that would otherwise be abandoned.Drawing on decades across immunology, biotech leadership, and translational medicine, Björn offers a grounded, operator-level view on what it actually takes to move from elegant science to real-world impact.As he puts it:(00:28:59) “In biotech, courageous decisions often look wrong—until years later.”This discussion goes beyond manufacturing alone. It explores why turning scientific concepts into ready-to-deploy healthcare solutions—complete with clinical data, regulatory pathways, scalable production, and high usability—remains one of the hardest industrial challenges of our time.What You'll Learn in This Episode1️⃣ Why biologics often fail late—after science already worked2️⃣ Why manufacturing is only one part of a deeper industrial bottleneck3️⃣ How Eleva approaches risk when others walk away4️⃣ Why courage, not optimization, drives breakthrough biotech decisions5️⃣ How AI supports discovery—without replacing human judgment6️⃣ What Europe gets right—and still gets wrong—about scaling biotech

On this episode Justin invites first time guest, Kevin Crosby, Managing Director, Healthcare and Life Sciences at TestMu AI. With over thirty years of experience in the provider, payer and Life Sciences spaces, Kevin focuses on helping organizations bring software to market with confidence by leveraging AI to automate software engineering. Justin and Kevin share insights on AI leadership in healthcare today. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Foresters know degraded forests all too well. You're out on a woods-walk with an enthusiastic landowner, but your eyes go straight to the poor growing stock, invasive plants, and eroded forest soils – the fingerprints of past degradation. Regardless, you set about the complex task of developing a prescription that will nudge this forest towards a brighter future. Foresters don't always think of themselves as restorationists, but in many ways, the tools of silviculture are the tools of restoration. In this episode of SilviCast, we dive into the science and practice of forest restoration with John Stanturf, visiting professor at the Estonian University of Life Sciences and Senior Forest Restoration Specialist with InNovaSilva. With more than 30 years of experience researching forest restoration in both temperate and tropical forests around the world, John brings a global perspective to the question of what it means to restore a forest. Send us a text

Welcome to the Podcast of Southwest Bible Fellowship in Tempe, Arizona. WHO ARE WE? • We are a group of people who are committed to living the grace life as set forth by the apostle of the Gentiles, the Apostle Paul. • We come together to study our Bibles, and yes, we believe we have God's perfect Word in the King James Bible. It and it alone is our final authority in all matters of faith and practice! • We do not come together and study our Bibles for the intent of being smarter than others. We understand that knowledge for the sake of knowledge is purely vain and serves no Godly purpose. • We do come together and study our Bibles for the intent of knowing our Lord Jesus Christ and the power of His resurrection. (Philippians 3:10) • We do come together and study our Bibles to understand that we have been crucified with Christ; nevertheless we live; yet not us, but Christ liveth in us: and the life which we now live in the flesh, we live by the faith of the Son of God, who loved us and gave himself for us. (Galatians 2:20) • We do come together and study our Bibles to understand that because Jesus Christ shed His blood for us and we should not live for ourselves but for Him, who died for us and rose again. (2 Cor. 5:15) • We do not claim to have attained to these lofty goals, but we press toward the mark of the prize of the high calling of God in Christ Jesus. (Philippians 3:14) You can donate to this ministry through www.butnow.org and the PayPal button on the homepage.

In this episode of Tiny Show and Tell Us, we learn that humans aren't the only mammals who menstruate. We explore the fulvous fruit bat's 33‑day cycle, how reproductive biology differs across species, and why scientists still don't fully understand why menstruation evolved in the first place. Then we take a deep dive into the world of mycotoxins: dangerous compounds produced by fungi. We cover how these toxins form, why they're so hard to eliminate, and risks they pose to agriculture, livestock, and human health.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Shannon Burkett has lived about six lives. Broadway actor. SNL alum. Nurse. Filmmaker. Advocate. Cancer survivor. And the kind of person who makes you question what you've done with your day. She wrote and produced My Vagina—the stop-motion musical kind, not the cry-for-help kind—and built a global movement after her son was poisoned by lead dust in their New York apartment. Out of that came LEAD: How This Story Ends Is Up to Us, a documentary born from rage, science, and maternal defiance. We talked about everything from The Goonies to Patrick Stewart to the quiet rage of parenting in a country that treats public health like a hobby. This episode is about art, anger, resilience, and what happens when an unstoppable theater nerd turned science geek Jersey girl collides with an immovable healthcare system.RELATED LINKSShannon Burkett Official SiteLEAD: How This Story Ends Is Up to UsEnd Lead PoisoningLinkedIn: Shannon BurkettBroadwayWorld ProfileFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sarah Smith, Qualitative Specialist and Global Behavioral Science Strategy Lead at Oracle Life Sciences, is focused on the critical role of behavioral science in improving recruitment and retention in clinical trials.  Oracle Life Sciences is working to address historical underrepresentation in clinical trials by combining behavioral insights with integrated technologies to identify at-risk populations and understand barriers to participation. Using nudges to encourage trial participation, conducting decentralized trials, and applying AI to reshape patient engagement are strong tools for building trust and improving accessibility. Sarah explains, "Behavioral science is about understanding behavior. It draws from a number of disciplines like psychology, anthropology, and behavioral economics. But what it tells us is that people aren't rational. They don't always do the things that we expect them to do. So if we want to engage people, if we want to engage them properly, if we want to ensure that all the things we do are equitable and have an equal playing field, then we need to really understand why people do the things they do and to try and help us make sense of that in a way that encompasses everybody."   "We see treatment and technology advancing, but there are many communities that aren't part of that still, that are underrepresented. Factors like gender, ethnicity, culture, conditions that carry a stigma, socioeconomic issues, and geographic limitations - all of these things can limit the opportunity, ability, and willingness of individuals to participate in clinical trials. And that means the impact of those trials is less generalizable because those people are not represented. They're just simply not there. So the treatment that is aimed at these people is not measured in those groups. Oracle is working to address this by combining a deeper understanding of behavior with integrated technology to try to close this gap in representation to give more inclusive patient-centered care that unifies clinical, behavioral, and safety data across settings. To give a more holistic view, to give more coordinated care, to identify risks earlier, to identify patients that perhaps just need a bit more attention - a more personalized engagement."   #OracleLifeSciences #lifesciences #ClinicalResearch #PatientCentricity #PatientEngagement #ClinicalTrials #Healthliteracy #BehavioralScience #HealthEquity #AI #Healthcare #Diversity #Inclusion #MedicalResearch #Innovation Oracle.com/life-sciences  Listen to the podcast here  

Sarah Smith, Qualitative Specialist and Global Behavioral Science Strategy Lead at Oracle Life Sciences, is focused on the critical role of behavioral science in improving recruitment and retention in clinical trials.  Oracle Life Sciences is working to address historical underrepresentation in clinical trials by combining behavioral insights with integrated technologies to identify at-risk populations and understand barriers to participation. Using nudges to encourage trial participation, conducting decentralized trials, and applying AI to reshape patient engagement are strong tools for building trust and improving accessibility. Sarah explains, "Behavioral science is about understanding behavior. It draws from a number of disciplines like psychology, anthropology, and behavioral economics. But what it tells us is that people aren't rational. They don't always do the things that we expect them to do. So if we want to engage people, if we want to engage them properly, if we want to ensure that all the things we do are equitable and have an equal playing field, then we need to really understand why people do the things they do and to try and help us make sense of that in a way that encompasses everybody."   "We see treatment and technology advancing, but there are many communities that aren't part of that still, that are underrepresented. Factors like gender, ethnicity, culture, conditions that carry a stigma, socioeconomic issues, and geographic limitations - all of these things can limit the opportunity, ability, and willingness of individuals to participate in clinical trials. And that means the impact of those trials is less generalizable because those people are not represented. They're just simply not there. So the treatment that is aimed at these people is not measured in those groups. Oracle is working to address this by combining a deeper understanding of behavior with integrated technology to try to close this gap in representation to give more inclusive patient-centered care that unifies clinical, behavioral, and safety data across settings. To give a more holistic view, to give more coordinated care, to identify risks earlier, to identify patients that perhaps just need a bit more attention - a more personalized engagement."   #OracleLifeSciences #lifesciences #ClinicalResearch #PatientCentricity #PatientEngagement #ClinicalTrials #Healthliteracy #BehavioralScience #HealthEquity #AI #Healthcare #Diversity #Inclusion #MedicalResearch #Innovation Oracle.com/life-sciences  Download the transcript here  

As we kick off 2026, Mindy sits down with Inizio Ignite Global President, Remco op den Kelder, to discuss the industry forces shaping the year ahead for life sciences companies.    Panel – Mindy McGrath, Remco op den Kelder   Recording & Editing – Mike Liberto, Rachel Skonecki    For additional discussion, please contact us at TrendingHealth.com.

Send us a textIn this exciting episode of The Wealth Vibe Show, host Vinki Loomba sits down with Salvatore  Buscemi, CEO and co-founding partner of Brahmin Partners, a private multifamily office managing a diverse portfolio with investments in SpaceX, Stripe, and Thrive Bioscience. Together, they explore the world of ultra-wealthy investors, delving into the strategies and decisions that shape their wealth-building approach.Key Takeaways:The World of the .001%: Salvatore  reveals how the ultra-wealthy, including some of the world's richest families, approach investments. Lessons from the Inside: Salvatore  shares his personal journey of transitioning from medicine to finance and his early experiences working with prominent families.The Scarcity vs. Abundance Mindset: Salvatore  contrasts the mindset of the middle class with that of the ultra-wealthy.The Importance of Relationships: Salvatore  emphasizes how crucial it is to build meaningful, long-lasting relationships in high-net-worth circles.Investing in Life Sciences and Real Estate: Salvatore  discusses the sectors currently attracting the attention of the ultra-wealthy.Episode Timestamps:00:00 - 06:30: Salvatore 's journey from aspiring doctor to finance and wealth management, working with the .001%06:30 - 12:00: How Salvatore  transitioned into the investment world, lessons from a mentor, and starting his first fund12:00 - 18:00: The mindset of ultra-wealthy families and the importance of long-term investing18:00 - 24:00: The significance of relationships in building wealth and how Salvatore  approaches networking in elite circles24:00 - 30:00: Investment strategies for the ultra-wealthy—what they look for and avoid30:00 - 36:00: Life sciences and Class A real estate as the future of family office investments36:00 - 42:00: The risks of liquidity and why wealth-building requires thinking beyond the short-term42:00 - 47:00: Salvatore  shares insights on the future of energy, space exploration, and how these sectors will define the next decade of wealth creation47:00 - 50:00: Rapid-fire round: Salvatore 's thoughts on the best investments, books, and underrated wealth-building strategies

It's no exaggeration to say that polio shaped modern medicine. Before a vaccine was available, polio outbreaks left thousands of people paralyzed, with some unable to breathe. But, in 1928, the development of the iron lung meant that, for the first time, humans could rely on a machine to stay alive. In this episode, we trace the rise of polio in the early 20th century, the science behind the virus, and the race to save lives. From early resuscitation experiments to the unexpected inspiration behind the iron lung, we uncover the innovation, ethical dilemmas, and human stories that defined this era, hearing from two people whose early childhoods and families were dramatically shaped by the disease. Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today on the Invest In Her Podcast, host Catherine Gray interviews Judyanna Yu, Founding Partner of One Six 8 Ventures. Judyanna is a seasoned finance executive and venture capitalist with nearly two decades of experience as a CFO across VC-backed public and private medtech and biotech companies. Based in Calgary, she leads One Six 8 Ventures, a venture capital fund focused on high-growth medtech opportunities in active M&A markets, with a particular emphasis on under-ventured regions. Drawing from a global career that spans eight cities across North America and Asia, Judyanna brings deep expertise in capital formation, financial governance, and scaling breakthrough technologies with real-world, life-saving impact. In this episode, Catherine and Judyanna explore what it takes to evaluate and scale transformative medical technologies, the importance of disciplined financial leadership in venture-backed companies, and how global networks can accelerate innovation beyond traditional venture hubs. Judyanna shares insights from her transition from CFO to fund founder, discusses the role of physician and operator-led diligence in medtech investing, and offers perspective on how founders can position themselves for sustainable growth and successful exits. The conversation also highlights the critical need to support innovation in overlooked markets and how intentional capital deployment can bring world-changing healthcare solutions to a global stage.

In today's Cloud Wars Minute, I explore how AI and healthcare are intersecting at an unprecedented pace.Highlights00:14 — Discoveries in healthcare are coming at an unprecedented pace. Capabilities have never been greater, and new methods of consulting with and treating patients are consistently emerging. However, all of this progress brings with it a significant administrative burden, because the more variables you introduce, the more complexity arises.00:34 — The key to unraveling this complexity and alleviating the burden on healthcare professionals is AI. Microsoft has announced that Anthropic has added tools, connectors, and skills to Claude in Microsoft Foundry. These new capabilities enable healthcare and life sciences organizations to leverage advanced reasoning, agentic workflows, and model intelligence.01:30 — Claude for Healthcare provides domain-specific tools and resources to support both medical and operational workflows, covering a wide range of use cases such as patient care, triage, coordination, and claims processing. Claude for Life Sciences helps accelerate research and development by connecting to scientific platforms and enabling the generation of high-quality protocol materials with far greater ease.02:23 — It's important to note that these services are delivered through Foundry, which benefits from a secure, enterprise-ready foundation provided by Microsoft Azure. This enables companies to scale their capabilities securely and compliantly. AI is most powerful and impactful when next-generation models like Claude are paired with infrastructure such as Foundry. Visit Cloud Wars for more.

Michael Kramer was 19 when cancer ambushed his life. He went from surfing Florida beaches to chemo, radiation, and a bone marrow transplant that left him alive but carrying a chronic disease. He had necrosis in his knees and elbows, lost his ability to surf for years, and found himself stuck in hospitals instead of the ocean. Yet he adapted. Michael picked up a guitar, built Lego sets, led support groups, and started sharing his story on Instagram and TikTok.We talk about masculinity, identity, and what happens when the thing that defines you gets stripped away. He opens up about dating in Miami, freezing sperm at a children's hospital, awkward Uber-for-sperm moments with his brother, and how meditation became survival. Michael lost his father to cancer when he was a teen, and that grief shaped how he lives and advocates today. He is funny, grounded, and honest about the realities of survivorship in your twenties. This episode shows what resilience looks like when you refuse to walk it off and choose to speak it out loud instead.RELATED LINKSMichael Kramer on InstagramMichael Kramer on TikTokMichael and Mom Inspire on YouTubeAshlee Cramer's BookUniversity of Miami Sylvester Comprehensive Cancer CenterStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode host Justin Barnes invites Tony Nunes, Senior Manager, Healthcare & Life Sciences at AMD for a look ahead to 2026. Along with a sneak peek at the upcoming conference calendar. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

As the Japanese police prepare for a raid on the Aum Shinrikyo compound, cult leader Shoko Asahara launches a desperate chemical weapons attack in downtown Tokyo. During the height of Monday morning rush hour, Aum terrorists target five commuter trains with sarin gas, killing 13 people and scarring the psyche of an entire nation. In the aftermath, survivors struggle to pick up the pieces of their lives and adapt to new realities.    SOURCES: Amarasingam, A. (2017, April 5). A history of sarin as a weapon. The Atlantic.  Brackett, D. W. Holy Terror: Armageddon in Tokyo. 1996. Cotton, Simon. “Nerve Agents: What Are They and How Do They Work?” American Scientist, vol. 106, no. 3, 2018, pp. 138–40.  Danzig, Richard; Sageman, Marc; Leighton, Terrance; Hough, Lloyd; Yuki, Hidemi; Kotani, Rui; Hosford, Zachary M.. Aum Shinrikyo: Insights Into How Terrorists Develop Biological and Chemical Weapons . Center for a New American Security. 2011 “Former ER Doctor Recalls Fear Treating Victims in 1995 Tokyo Sarin Attack.” The Japan Times, March 18, 2025.. Gunaratna, Rohan. “Aum Shinrikyo's Rise, Fall and Revival.” Counter Terrorist Trends and Analyses, vol. 10, no. 8, 2018, pp. 1–6.  Harmon, Christopher C. “How Terrorist Groups End: Studies of the Twentieth Century.” Strategic Studies Quarterly, vol. 4, no. 3, 2010, pp. 43–84. JSTOR, http://www.jstor.org/stable/26269787.  “IHT: A Safe and Sure System — Until Now.” The New York Times, 21 Mar. 1995. Jones, Seth G., and Martin C. Libicki. “Policing and Japan's Aum Shinrikyo.” How Terrorist Groups End: Lessons for Countering al Qa'ida, RAND Corporation, 2008, pp. 45–62.  Kaplan, David E. (1996) “Aum's Shoko Asahara and the Cult at the End of the World”. WIRED.  Lifton, Robert Jay. Destroying the World to Save It: Aum Shinrikyo, Apocalyptic Violence, and the New Global Terrorism. 1999. Murakami, Haruki. Underground: The Tokyo Gas Attack and the Japanese Psyche. Translated by Alfred Birnbaum and Philip Gabriel. 2001. Murphy, P. (2014, June 21). Matsumoto: Aum's sarin guinea pig. The Japan Times.  Reader, Ian. Religious Violence in Contemporary Japan: The Case of Aum Shinrikyo.  2000. Tucker, Jonathan B. “Chemical/Biological Terrorism: Coping with a New Threat.” Politics and the Life Sciences, vol. 15, no. 2, 1996, pp. 167–83.  Ushiyama, Rin. “Shock and Anger: Societal Responses to the Tokyo Subway Attack.” Aum Shinrikyō and Religious Terrorism in Japanese Collective Memory., The British Academy, 2023, pp. 52–80.  Williams, Richard. 2003. “Marathon Man.” The Guardian, May 16, 2003. “Woman bedridden since AUM cult's 1995 sarin gas attack on Tokyo subway dies at 56.” The Mainichi (English), 20 Mar. 2020, “30 Years After Sarin Attack — Lessons Learned / Brother Kept Diary For Sister Caught in Sarin Attack, Chronicling Her 25-Year Struggle With Illness” The Japan News, 19 Mar. 2025, Learn more about your ad choices. Visit megaphone.fm/adchoices

Daniel Garza had momentum. Acting roles, directing gigs, national tours lined up. Then anal cancer stopped everything. Radiation wrecked his body, stripped him of control, and left him in diapers, staring down despair. His partner, Christian Ramirez, carried him through the darkest nights, changed his wounds, fought hospitals, and paid the price with his own health. Christian still lives with permanent damage from caregiving, but he stayed anyway.Together they talk with me about masculinity, sex, shame, friendship, and survival. They describe the friendships that vanished, the laughter that kept them alive, and the brutal reality of caregiving no one prepares you for. We get into survivor guilt, PTSD, and why even rocks need rocks. Daniel is now an actor, director, and comedian living with HIV. Christian continues to tell the unfiltered truth about what it takes to be a caregiver and stay whole. This episode gives voice to both sides of the cancer experience, the survivor and the one who stands guard. RELATED LINKSDaniel Garza IMDbDaniel Garza on InstagramDaniel Garza on FacebookChristian Ramirez on LinkedInLilmesican Productions Inc (Daniel & Christian)Stupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.